News
HBIO
5.09
+4.52%
0.22
Harvard Bioscience CFO Makes Bold Insider Move Signaling Confidence Ahead
TipRanks · 9h ago
Harvard Bioscience CFO Mark Frost acquires $25,000 common shares
Reuters · 22h ago
Weekly Report: what happened at HBIO last week (0323-0327)?
Weekly Report · 3d ago
Weekly Report: what happened at HBIO last week (0316-0320)?
Weekly Report · 03/23 10:17
Harvard Bioscience Directors Make Bold Insider Moves That Could Signal What’s Coming Next
TipRanks · 03/19 02:05
Harvard Bioscience Director Stephen J DeNelsky Acquires USD 48,700 in Common Shares
Reuters · 03/18 18:13
Harvard Bioscience Director William Snider Acquires USD 103,000 of Common Shares
Reuters · 03/18 11:32
Harvard Bioscience CEO Makes Bold Insider Move With Fresh Stock Purchase
TipRanks · 03/18 02:07
Harvard Bioscience CEO John D Duke acquires USD 25,050 of common shares
Reuters · 03/17 21:57
Harvard Bioscience Highlights CFO Appointment and Strategic Repositioning
TipRanks · 03/17 12:20
Harvard Bioscience Is Maintained at Speculative Buy by Benchmark
Dow Jones · 03/16 13:35
Harvard Bioscience Price Target Raised to $6.00/Share From $0.60 by Benchmark
Dow Jones · 03/16 13:35
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $6
Benzinga · 03/16 13:26
Harvard Bioscience price target adjusted to $6 at Benchmark after reverse split
TipRanks · 03/16 12:15
HARVARD BIOSCIENCE INC <HBIO.O>: BENCHMARK RAISES TARGET PRICE TO $6 FROM $0.60
Reuters · 03/16 11:17
Weekly Report: what happened at HBIO last week (0309-0313)?
Weekly Report · 03/16 10:16
U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics
Reuters · 03/16 10:00
Upcoming Stock Splits This Week (March 16–20, 2026) – Stay Invested
TipRanks · 03/15 13:20
Harvard Bioscience trading halted, news pending
TipRanks · 03/13 23:56
Harvard Bioscience Is Maintained at Speculative Buy by Benchmark
Dow Jones · 03/13 12:58
More
Webull provides a variety of real-time HBIO stock news. You can receive the latest news about Harvard Biosci through multiple platforms. This information may help you make smarter investment decisions.
About HBIO
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.